Evaluation of Take and Safety of a Smallpox Vaccine in Healthy Young Adults

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

230 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-09-30

Study Completion Date

2007-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Primary Objective:

To estimate the smallpox vaccination take rate in healthy young adults not previously vaccinated with a smallpox vaccine.

Secondary Objectives:

To describe antibody response to vaccination and evaluate the take for each subject at various timepoints for each batch and pooled batches and to evaluate local signs, symptoms, and overall safety in healthy young adults not previously vaccinated with a smallpox vaccine.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Long-Term Study of Healthy Adults Vaccinated With One Dose of Smallpox Vaccine (LISTER Strain)

NCT00998543

Smallpox

COMPLETED

A Safety Study of Live Attenuated Varicella Vaccines in Healthy Adults, Adolescents and Children

NCT02965404

Varicella

COMPLETED PHASE1

A Phase III Clinical Trial Assessing the Immunogenicity and Safety of Lyophilized Live-Attenuated Varicella Vaccine in Healthy Subjects Aged 13 to 55 Years

NCT06592456

Chickenpox Vaccines

COMPLETED PHASE3

A Clinical Study of a Zoster Vaccine in Healthy Adults >= 40 Years

NCT04072497

Herpes Zoster

COMPLETED PHASE1/PHASE2

Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years Old

NCT05015686

Varicella

ENROLLING_BY_INVITATION PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Smallpox Poxvirus Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Smallpox vaccine, LISTER strain, from chick embryo cells

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged 18 to 25 years on the day of screening
* Informed consent form signed
* Able to attend all scheduled visits and to comply with all trial procedures
* For a woman, inability to bear a child or negative serum pregnancy test performed at screening (Visit 01)
* Subject entitled to national social security
* Subject registered in the French file of healthy volunteers in clinical trials
* For a woman of child-bearing potential: use of an effective method of contraception (hormonal or barrier method) from at least 3 months prior to screening to 3 months following trial vaccination
* For a woman, inability to bear a child or negative urine pregnancy test.

Exclusion Criteria

* Previous smallpox vaccination confirmed by vaccination record or typical scar
* Participation in another trial in the 3 months before or during the trial period
* Acute intercurrent or chronic illness during the trial
* Breast-feeding
* Allergy or sensitivity to any known components of vaccinia immune globulin or previous reaction to immunoglobulins or trial vaccine
* Congenital or acquired immunodeficiency or immunosuppressive therapy or any treatment including corticosteroids
* Treatment with antiviral drugs within 1 month before vaccination
* History of organ or bone marrow transplant or skin disorders
* Personal or family history of autoimmune disease or cardiac disease, including cardiac risk factors
* History or current central nervous system disease
* Ongoing acute infectious disease
* Blood or blood-derived products received in the past 6 months
* Any vaccination with a live-attenuated vaccine within the 60 days or other vaccines within 40 days preceding the trial vaccination
* Vaccination planned in the 8 weeks following the trial vaccination
* Planned or foreseeable close contact after vaccination with infants less than 12 months, or with immuno-suppressed persons, pregnant and/or lactating woman, or practice of contact or water sports after vaccination before the crust separates
* Skin wound near the vaccination site
* Apparent lack of personal hygiene
* Subject deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized without his/her consent
* HIV, hepatitis B or hepatitis C seropositivity (screening tests)
* Abnormal lab values for hematological parameters or cardiac enzyme (screening tests)
* Feverish illness (oral temperature \>=37.5°C, rectal equivalent temperature \>=38.0°C) on the day of vaccination.

Minimum Eligible Age

18 Years

Maximum Eligible Age

25 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes